HOOKIPA PharmaHOOK 50 PS Ratio is 0.98 as of Jun. 30, 2026, which is 76% below its 10-year median of 4.06. GuruFocus rates HOOK with a GF Score™ of 50/100 and a GF Value™ of $2.78 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 935 Biotechnology companies, HOOKIPA Pharma ranks better than 92.51% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, HOOKIPA Pharma's share price is $1.15.
HOOKIPA Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2025 was $1.18. Hence, HOOKIPA Pharma's PS Ratio for today is 0.98.
Warning Sign:
HOOKIPA Pharma Inc stock PS Ratio (=0.98) is close to 1-year high of 1.04.
The historical rank and industry rank for HOOKIPA Pharma's PS Ratio or its related term are showing as below:
HOOK'
s PS Ratio Range Over the Past 10 Years
Min: 0.34 Med: 4.06 Max: 27.94
Current: 0.98
During the past 8 years, HOOKIPA Pharma's highest PS Ratio was 27.94. The lowest was 0.34. And the median was 4.06.
HOOK's PS Ratio is ranked better than 92.51% of 935
companies
in the Biotechnology industry
Industry Median: 9.37
vs HOOK: 0.98
HOOKIPA Pharma Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of HOOKIPA Pharma was -72.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -14.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -20.40% per year.
During the past 8 years, HOOKIPA Pharma's highest 3-Year average Revenue per Share Growth Rate was 6.30% per year. The lowest was -34.30% per year. And the median was -22.90% per year.
Back to Basics: PS Ratio
HOOKIPA Pharma (OTCPK:HOOK) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
HOOKIPA Pharma PS Ratio Related Terms
HOOKIPA Pharma PS Ratio Historical Data
* Premium members only.
The historical data trend for HOOKIPA Pharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, HOOKIPA Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HOOKIPA Pharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where HOOKIPA Pharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
HOOKIPA Pharma's Share Price of today is $1.15. HOOKIPA Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.18.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
HOOKIPA Pharma (HOOK) has a PS Ratio of 0.98 as of Jun. 30, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on HOOKIPA Pharma and its competitors. This is 76% below median its historical median of 4.06. Over the past decade, HOOKIPA Pharma's PS Ratio has ranged from 0.34 to 27.94. According to the industry distribution chart, HOOKIPA Pharma ranks #70 out of 935 companies in the Biotechnology industry, placing it in the top 7.5%.
Is HOOKIPA Pharma's PS Ratio too high?
HOOKIPA Pharma's current PS Ratio of 0.98 is 76% below median its 10-year median of 4.06. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 27.94. The Biotechnology industry median PS Ratio is 9.37. HOOKIPA Pharma's value of 0.98 is 89.5% below this industry median. Based on the distribution chart, HOOKIPA Pharma ranks #70 out of 935 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HOOKIPA Pharma has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's PS Ratio compare to COCP and LNAI?
According to the Biotechnology industry distribution chart, HOOKIPA Pharma ranks #70 out of 935 companies for PS Ratio. This places HOOKIPA Pharma in the top 8% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.37. HOOKIPA Pharma's value of 0.98 is 89.5% below this benchmark. Historically, HOOKIPA Pharma's own PS Ratio has ranged from 0.34 to 27.94 over the past decade. While the company's 10-year median is 4.06 vs. the industry median of 9.37, HOOKIPA Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.37, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HOOKIPA Pharma's current PS Ratio of 0.98 is 89.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on HOOKIPA Pharma and its competitors. For the Biotechnology industry, the median PS Ratio is 9.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HOOKIPA Pharma's current PS Ratio is 0.98, which is 76% below median its own 10-year median of 4.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
Based on GuruFocus' analysis, HOOKIPA Pharma (HOOK) is currently considered Possible Value Trap. The stock's GF Value™ is $2.78, compared to a current price of $1.15 — trading 58.6% below its estimated fair value. The current PS Ratio is 0.98, which is 76% below median its 10-year median of 4.06 and 89.5% below the Biotechnology industry median of 9.37. HOOKIPA Pharma's overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current PS Ratio is 0.98 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HOOKIPA Pharma (HOOK) Overvalued in 2026?
Based on GuruFocus' analysis, HOOKIPA Pharma stock appears to be undervalued.
The current stock price of $1.15 is trading 58.6% below its estimated GF Value™ of $2.78.
GuruFocus considers HOOKIPA Pharma to be Possible Value Trap.
Key valuation signals for HOOK:
PS Ratio: 0.98 (76% below median its 10-year median of 4.06)
GF Value™: $2.78 vs. price of $1.15 (58.6% below fair value)
Industry Position: 89.5% below the Biotechnology median (#70 of 935)
No single metric tells the full story. See the HOOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
50GF Score
Get the complete analysis for HOOK
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOOK has been successfully added to your 
